All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)

This study is looking at a potential new treatment called nerandomilast (also known as BI 1015550) for adults living with fibrosing interstitial lung disease. This is a condition that causes progressive scarring in the lungs, making it harder to breathe over time. The main aim of the trial is to find out whether nerandomilast can safely slow down the loss of lung capacity compared to a placebo (a dummy tablet that looks identical but contains no active drug). Taking part lasts for at least 52 weeks (one year). During this time, doctors will track changes in your breathing using standard lung function tests and chest scans. Half of the participants will receive the real medicine, and the other half will receive the placebo. Neither you nor your doctor will know which one you are taking.

At a glance

Status
Authorised
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Enrolment target
143
Start
21 Oct 2026

What is this study about?

Interstitial lung disease is a general term for a large group of conditions that cause inflammation and scarring in the lungs. When scarring happens, doctors call it fibrosis. Over time, this scarring makes the lung tissue stiff and thick, which can leave you feeling short of breath, tired, and struggling with everyday activities. Finding treatments that can stop or slow down this scarring is a top priority for lung specialists.

This study, called FIBRONEER-ACT, is testing a new experimental medicine called nerandomilast. Researchers hope that it can protect lung tissue and keep your lungs working better for longer. To prove that it works, this Phase III trial compares nerandomilast directly against a dummy pill called a placebo.

The trial is 'double-blind', meaning neither you nor your study doctor will choose or know which tablet you receive. This ensures the results are completely fair and reliable. By taking part, you could help doctors discover a new treatment option for people living with progressive lung scarring across the UK and worldwide.

Key takeaways

  • Tests whether nerandomilast can slow down lung scarring in interstitial lung disease.
  • Open to adults aged 18 and older with progressive lung fibrosis.
  • Lasts for at least 52 weeks (one year) with regular clinic check-ups.
  • Half of the participants receive the trial drug, and half receive a dummy pill (placebo).
  • Taking part is voluntary, and you can withdraw at any time without affecting your NHS care.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with a type of interstitial lung disease that causes lung scarring (pulmonary fibrosis). The study focuses on people whose condition is at risk of getting worse over time.

Men and women of any age above 18 can take part. However, your lung specialist will need to run specific breathing tests and look at your medical history to ensure your lungs are suitable for the trial and that it is safe for you to join.

You may not be eligible if you have other serious health problems, such as severe heart or kidney disease, or if you are taking certain medicines that could clash with the study drug. Your study doctor will review all your current prescriptions before you join.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with interstitial lung disease (ILD) with lung scarring.
  3. My lung condition has shown signs of progressing or worsening.
  4. I am able and willing to attend regular hospital check-ups for at least one year.
  5. I am happy to take a daily tablet that may be either the study drug or a placebo.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for at least 52 weeks (about one year), with regular follow-up visits at a hospital clinic. You will be asked to take a tablet daily, which will be either nerandomilast or a matching placebo.

During your clinic visits, the research team will closely monitor your health. You will have regular breathing checks, such as spirometry tests (where you blow into a machine to measure your lung capacity). You will also have blood tests, health questionnaires, and specialised chest scans (CT scans) to see how your lungs are doing.

Travel expenses are often covered, and the study team will support you throughout the entire process. You will be able to contact them between visits if you feel unwell or notice any new symptoms.

Potential risks and benefits

Taking part may help slow down the progression of your lung condition if you receive the active medicine, but this cannot be guaranteed. You will also receive very close, expert medical monitoring of your lung health throughout the trial. However, there is a chance you will receive the placebo, which contains no active drug. Like all new medicines, nerandomilast may cause side effects, which the study doctor will explain in detail. You are free to leave the trial at any point, without giving a reason, and your regular NHS medical care will not be affected in any way.

Locations (9)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Belgium
  • —
    Unverified
    France
  • —
    Unverified
    Netherlands
  • —
    Unverified
    Finland
  • —
    Unverified
    Italy
  • —
    Unverified
    Spain
  • —
    Unverified
    Germany
  • —
    Unverified
    Poland
  • —
    Unverified
    Austria

Common questions

What is a placebo?

A placebo is a dummy pill that looks, smells, and tastes just like the real medicine but contains no active ingredients. It helps doctors see if the real drug works better than no treatment.

Can I choose to take the real medicine instead of the placebo?

No. A computer randomly decides who receives the study medicine and who receives the placebo. Neither you nor your doctor can choose or find out which one you are taking during the study.

Will taking part cost me anything?

No. The study medication, clinic visits, and all trial tests are free. Most trials also help reimburse reasonable travel costs to and from the hospital.

Can I carry on taking my usual lung medicines?

In many cases, yes. The study team will review all your existing medicines to check if they are safe to take alongside the trial treatment.

What happens if my condition gets worse during the trial?

Your safety comes first. The medical team tracks your health closely, and if your lung condition worsens or you feel unwell, the doctors can change your treatment or withdraw you from the study immediately.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.